Case 1: Dr. Rena Callahan presented a case of de novo metastatic TNBC highlighted debate over first-line therapy and local treatment. The patient received gemcitabine, carboplatin, and pembrolizumab, achieving ctDNA negativity after four cycles.

Case 2: Dr. Kelly McCann presented a TNBC case achieving pCR after neoadjuvant chemotherapy highlighted the role of BRCA testing, neoadjuvant therapy for small tumors, adjuvant olaparib in BRCA+ disease, and evolving use of TILs.

Case 3: Dr. Hannah Chang presented a metastatic TNBC case explored pembrolizumab rechallenge after immune hepatitis. Panelists weighed recurrence risk, NCCN guidance, and variable PD-L1 expression when deciding whether to resume immunotherapy.

Case 4: Dr. Adrienne Waks presented a young patient with BRCA1-mutated TNBC and residual disease after neoadjuvant therapy prompted discussion on adjuvant olaparib, capecitabine, pembrolizumab, or observation to reduce recurrence risk.

Panelists favored olaparib plus pembrolizumab over capecitabine for BRCA1-mutated TNBC. They discussed oophorectomy benefits, low MDS risk, and sequencing PARP inhibitors before capecitabine in higher-risk disease.